PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
From:
Published online Jul 2, 2012. doi: 10.2147/BTT.S20659
Table 2
Biologic plus methotrexate versus methotrexate for total X-ray score in rank order
MedicationReferenceFollow-up periodNumberSMD (95% CI)
InfliximabLipsky et al1354 weeks173−0.63 (−0.87 to −0.38)
AdalimumabKeystone et al1112 months299−0.45 (−0.68 to −0.22)
Breedveld et al1412 months372−0.45 (−0.65 to −0.24)
Pooled−0.45 (−0.60 to −0.29)
RituximabTak et al1712 months443−0.46 (−0.65 to −0.28)
Cohen et al1624 months468−0.41 (−0.59 to −0.22)
Pooled−0.44 (−0.58 to −0.30)
EtanerceptEmery et al712 months476−0.37 (−0.55 to −0.19)
Klareskog et al612 months430−0.36 (−0.55 to −0.17)
Pooled−0.37 (−0.50 to −0.23)
Certolizumab pegolSmolen et al1024 weeks373−0.29 (−0.51 to −0.08)
AbataceptKremer et al2012 months586−0.21 (−0.39 to −0.04)
Westhovens et al2112 months459−0.33 (−0.51 to −0.14)
Pooled−0.26 (−0.39 to −0.14)
GolimumabEmery et al1512 months541−0.09 (−0.26 to +0.08)
Note: Bold text indicates pooled results for each agent.
Abbreviations: CI, confidence interval; SMD, standardized mean difference.
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press